CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)
Condition(s) studied
Study summary
The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.
Eligibility
Primary outcome measure(s)
- Percentage of participants with virological failure — Week 48
Two consecutive viral load (VL) measurements ≥50 copies/mL after having achieved VL \<50 copies/mL - Percentage of participants with virological failure — Week 24
ii. A single VL ≥50 copies/mL followed by permanent treatment discontinuation or loss to follow-up after previously achieving VL \<50 copies/mL; or discontinuation with VL ≥50 copies/mL - Percentage of participants with virological failure — Week48
A VL ≥50 copies/mL
Trial sites (13)
| Facility | City | Region | Status |
|---|---|---|---|
| Victor Dupuy Hospital | Argenteuil | France | |
| Pellegrin Hospital | Bordeaux | France | |
| Saint André Hospital | Bordeaux | France | |
| Raymond poincaré Hospital | Garches | France | |
| Franco-British Hospital (Fbh) | Levallois-Perret | France | |
| Hotel Dieu Hospital | Nantes | France | |
| Archet 1Hospital | Nice | France | |
| Bichat Claude Bernard Hospital | Paris | France | |
| Hotel Dieu Hospital | Paris | France | |
| Necker Hospital | Paris | France | |
| Pitié Salpêtrière Hospital | Paris | France | |
| Saint Antoine Hospital | Paris | France | |
| Tourcoing Hospital | Tourcoing | France |
More Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07402044 on ClinicalTrials.gov ↗ ← All trials in France